Notice2025-15135
Notice of Diabetes Mellitus Interagency Coordinating Committee Meeting
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
August 8, 2025
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The Diabetes Mellitus Interagency Coordinating Committee (DMICC) will hold a meeting on September 30th, 2025. The topic for this meeting will be "COVID-19 and New-Onset Diabetes."
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 151 (Friday, August 8, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 151 (Friday, August 8, 2025)]
[Notices]
[Pages 38478-38479]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-15135]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Notice of Diabetes Mellitus Interagency Coordinating Committee
Meeting
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Diabetes Mellitus Interagency Coordinating Committee
(DMICC) will hold a meeting on September 30th, 2025. The topic for this
meeting will be ``COVID-19 and New-Onset Diabetes.''
DATES: The meeting will be held on September 30th, 2025, from 1:00 p.m.
to 4:00 p.m. EDT.
ADDRESSES: This meeting will be held via Teams online video
conferencing platform. For details, and to register, please go to the
virtual event's page: <a href="https://events.gcc.teams.microsoft.com/event/df4251d8-f786-46a0-910d-50c602572311@14b77578-9773-42d5-8507-251ca2dc2b06">https://events.gcc.teams.microsoft.com/event/df4251d8-f786-46a0-910d-50c602572311@14b77578-9773-42d5-8507-251ca2dc2b06</a>.
[[Page 38479]]
FOR FURTHER INFORMATION CONTACT: For further information concerning
this meeting, including a draft agenda, which will be posted when
available, see the DMICC website, <a href="https://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/diabetes-mellitus-interagency-coordinating-committee-dmicc?dkrd=lgdmn0022">https://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/diabetes-mellitus-interagency-coordinating-committee-dmicc?dkrd=lgdmn0022</a>, or contact Dr. William
Cefalu, Executive Secretary of the Diabetes Mellitus Interagency
Coordinating Committee, National Institute of Diabetes and Digestive
and Kidney Diseases, 6707 Democracy Boulevard, Democracy 2, Room 6037,
Bethesda, MD 20892, telephone: 301-435-1011; email: <a href="/cdn-cgi/l/email-protection#781c15111b1b381519111456161110561f170e"><span class="__cf_email__" data-cfemail="2f4b42464c4c6f424e46430141464701484059">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: In accordance with 42 U.S.C.285c-3, the
DMICC, chaired by the National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) and comprising members of the Department of
Health and Human Services and other federal agencies that support
diabetes-related activities, facilitates cooperation, communication,
and collaboration on diabetes among government entities. DMICC
meetings, held several times a year, provide an opportunity for
Committee members to learn about and discuss current and future
diabetes programs in DMICC member organizations and to identify
opportunities for collaboration. The September 30, 2025 DMICC meeting
will focus on ``COVID-19 and New-Onset Diabetes.''
Any member of the public interested in presenting oral comments to
the Committee should notify the contact person listed on this notice at
least 5 days in advance of the meeting. Interested individuals and
representatives or organizations should submit a letter of intent, a
brief description of the organization represented, and a written copy
of their oral presentation in advance of the meeting. Only one
representative of an organization will be allowed to present; oral
comments and presentations will be limited to a maximum of 5 minutes.
Printed and electronic copies are requested for the record. In
addition, any interested person may file written comments with the
Committee by forwarding their statement to the contact person listed on
this notice. The statement should include the name, address, telephone
number and when applicable, the business or professional affiliation of
the interested person. Because of time constraints for the meeting,
oral comments will be allowed on a first-come, first-serve basis.
Members of the public who would like to receive email notification
about future DMICC meetings can select to be added to the DMICC
listserv when registering on the meeting's event page: <a href="https://events.gcc.teams.microsoft.com/event/df4251d8-f786-46a0-910d-50c602572311@14b77578-9773-42d5-8507-251ca2dc2b06">https://events.gcc.teams.microsoft.com/event/df4251d8-f786-46a0-910d-50c602572311@14b77578-9773-42d5-8507-251ca2dc2b06</a>.
Dated: July 31, 2025.
William T. Cefalu,
Director, Division of Diabetes, Endocrinology, and Metabolic Diseases,
National Institute of Diabetes and Digestive and Kidney Diseases,
National Institutes of Health.
[FR Doc. 2025-15135 Filed 8-7-25; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on August 8, 2025.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.